• Verastem priced an underwritten follow-on offering of 30,937,500 common shares at USD 8.00 per share.
• Deal includes pre-funded warrants for 312,503 shares at USD 7.9999 each, with a USD 0.0001 exercise price.
• Gross proceeds expected to total about USD 250 million, before fees.
• Closing targeted for about Oct. 15, 2026, subject to customary conditions.
• Net proceeds earmarked for clinical development, including the VS-7375 program, working capital, and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014594734) on October 14, 2026, and is solely responsible for the information contained therein.